Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 184 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rifampin (RIF) Clear all
Completed Phase 1 Interventional Results available

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

NCT01765543
View directory record Official record
Conditions
Malignant Melanoma, Neoplasms
Interventions
Rifampin, Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Rogers, Arkansas • Pleasant Hill, California • Middletown, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

NCT04410094
View directory record Official record
Conditions
Healthy
Interventions
Lazertinib, Itraconazole, Rifampin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

NCT03340662
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-122, Itraconazole, Fluvoxamine, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

NCT06363630
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Itraconazole, Rifampin, Golcadomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Atlanta, Georgia • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

NCT03563950
View directory record Official record
Conditions
Healthy Participants
Interventions
Rifampin, BMS-986224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 4 Interventional

Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics

NCT03012529
View directory record Official record
Conditions
Osteomyelitis, Diabetes, Amputation
Interventions
Rifampin, Riboflavin Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 4, 2026, 2:51 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Azacytidine During Anti-tuberculosis Therapy

NCT03941496
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
Azacitidine Injection
Drug
Lead sponsor
Andrew Dinardo
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

NCT05255276
View directory record Official record
Conditions
Healthy Adults
Interventions
Sitravatinib 50 mg, Sitravatinib 100 mg, Itraconazole, Rifampin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

NCT03624959
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ozanimod, Gemfibrozil, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 4, 2026, 2:51 AM EDT
Completed No phase listed Observational

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

NCT01587469
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Cepheid
Industry
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 4, 2026, 2:51 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement

NCT06489431
View directory record Official record
Conditions
Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation
Interventions
Chlorhexidine, Gentamicin, Rifampin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Mountain View, California • Chicago, Illinois • Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

NCT02804399
View directory record Official record
Conditions
Healthy
Interventions
PF-06463922, rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

NCT01954043
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib 150 mg twice a day (BID), Rabeprazole 40 mg once daily (OD), Rifampin 600 mg OD
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Goodyear, Arizona • Dallas, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.

NCT00777855
View directory record Official record
Conditions
Healthy
Interventions
warfarin plus rifampin, warfarin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

NCT02055703
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, itraconazole, rifampin, digoxin, donepezil
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

CYP3A4 Activity and Mineral Homeostasis

NCT02019875
View directory record Official record
Conditions
Vitamin D and Calcium Homeostasis
Interventions
Rifampin, Clarithromycin, Grapefruit Juice, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 2 Interventional

A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

NCT00000641
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ciprofloxacin hydrochloride, Ethambutol hydrochloride, Amikacin sulfate, Azithromycin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
16
States / cities
Torrance, California • Indianapolis, Indiana • St Louis, Missouri + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

NCT03723395
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
tucatinib, itraconazole, rifampin, gemfibrozil, repaglinide, tolbutamide, midazolam, digoxin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 4, 2026, 2:51 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406
View directory record Official record
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions
SPR720, Placebo, Open-label Standard of Care
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 3 Interventional

TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis

NCT00023335
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2005 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional

Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

NCT01401933
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Linifanib, Rifampin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Tucson, Arizona • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine

NCT02846519
View directory record Official record
Conditions
Healthy
Interventions
Esketamine, Rifampin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

NCT02807116
View directory record Official record
Conditions
Healthy Subjects
Interventions
Pacritinib, Rifampin, Pacritinib and Rifampin
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 4, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers

NCT02199392
View directory record Official record
Conditions
P-glycoprotein, Healthy Volunteers
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 4, 2026, 2:51 AM EDT